Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 1 |
| Orphan Autoimmune Disorders to 2017 - Introduction | 9 | 2 |
| Overview | 9 | 1 |
| GBI Research Report Guidance | 10 | 1 |
| Orphan Autoimmune Disorders to 2017 - Market Characterization | 11 | 6 |
| Market Forecasts | 11 | 1 |
| Revenue | 11 | 2 |
| Market Share of Orphan Diseases | 13 | 1 |
| Generic/Off-Label Share | 14 | 1 |
| Drivers and Restraints for the Global Orphan Autoimmune Disorders Therapeutics Market | 15 | 1 |
| Market Drivers | 15 | 1 |
| Strong Performance by Existing Branded Drugs and Expected Launch of Promising Products | 15 | 1 |
| High Unmet Needs and Orphan Drug Status to New Molecules | 15 | 1 |
| Market Restraints | 15 | 1 |
| Low Prevalence of Orphan Autoimmune Disorders | 15 | 1 |
| Lack of Specific Diagnostic Tests | 15 | 1 |
| Intense Competition from Generics and Off-Label Drugs | 16 | 1 |
| Orphan Autoimmune Disorders to 2017 - Geographical Landscape | 17 | 6 |
| Revenue Analysis by Geography | 17 | 2 |
| The US | 19 | 1 |
| Revenue | 19 | 1 |
| Top Five Countries of Europe | 20 | 1 |
| Revenue | 20 | 1 |
| Japan | 21 | 1 |
| Revenue | 21 | 2 |
| Orphan Autoimmune Disorders to 2017 - Therapeutic Landscape | 23 | 31 |
| Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecasts | 23 | 1 |
| Disease Overview | 23 | 2 |
| Revenue | 25 | 1 |
| Generic Share | 26 | 1 |
| Revenue Analysis by Country | 27 | 2 |
| Annual Cost of Treatment | 29 | 1 |
| Treatment Usage Patterns | 30 | 1 |
| Diseased Population | 31 | 1 |
| Treatment Seeking Population | 31 | 1 |
| Diagnosed Population | 31 | 1 |
| Treated Population | 31 | 1 |
| Major Marketed Products | 32 | 1 |
| Nplate (Romiplostim) | 32 | 1 |
| Promacta/Revolade (Eltrombopag) | 32 | 1 |
| Rhophylac (Rh0 (D) Immune Globulin (Human)) | 32 | 1 |
| Drivers and Restraints of the ITP Therapeutics Market | 33 | 1 |
| Market Drivers | 33 | 1 |
| Strong Performance by Existing Therapies for Chronic ITP to Drive the Market | 33 | 1 |
| High Unmet Needs and Orphan Drug Status to New Molecules Meant to Treat ITP | 33 | 1 |
| High Treatment seeking Population | 33 | 1 |
| Market Restraints | 33 | 1 |
| Lack of Specific Diagnostic Tests | 33 | 1 |
| Absence of Novel Specific Therapies in the R&D Pipeline | 33 | 1 |
| Global Myasthenia Gravis Therapeutics Market Forecasts | 34 | 1 |
| Disease Overview | 34 | 1 |
| Revenue | 35 | 1 |
| Generic Share | 36 | 1 |
| Revenue Analysis by Country | 37 | 2 |
| Annual Cost of Treatment | 39 | 1 |
| Treatment Usage Patterns | 40 | 1 |
| Diseased Population | 41 | 1 |
| Treatment Seeking Population | 41 | 1 |
| Diagnosed Population | 41 | 1 |
| Treated Population | 42 | 1 |
| Major Marketed Products | 42 | 1 |
| Mestinon (Pyridostigmine Bromide) | 42 | 1 |
| Drivers and Restraints of the Myasthenia Gravis Therapeutics Market | 42 | 1 |
| Market Drivers | 42 | 1 |
| Expected Launch of Promising Immunoglobulin Therapy to Drive the Market | 42 | 1 |
| Growth in the Treated Population | 42 | 1 |
| Market Restraints | 42 | 1 |
| Low Treatment Seeking Rate | 42 | 1 |
| Generic Dominance and Absence of Branded Drugs | 42 | 1 |
| Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Forecasts | 43 | 1 |
| Disease Overview | 43 | 1 |
| Revenue | 44 | 2 |
| Revenue Analysis by Country | 46 | 2 |
| Generic Share | 48 | 1 |
| Annual Cost of Treatment | 49 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Disease Population | 51 | 1 |
| Treatment Seeking Population | 51 | 1 |
| Diagnosis Population | 51 | 1 |
| Treated Population | 51 | 1 |
| Major Marketed Products | 52 | 1 |
| Rilutek (Riluzole) | 52 | 1 |
| Drivers and Restraints of the ALS Therapeutics Market | 52 | 1 |
| Market Drivers | 52 | 1 |
| Expected Launch of Promising Pipeline Molecules Will Drive the Growth of ALS Market In Future | 52 | 1 |
| The Rise in Awareness Among ALS Patients May Drive the ALS Market | 52 | 1 |
| High Unmet Needs and Orphan Drug Status for New Molecules Targeting ALS | 52 | 1 |
| Market Restraints | 52 | 1 |
| Low Diagnosis Rate | 52 | 1 |
| Patent Expiry of Rilutek | 53 | 1 |
| Orphan Autoimmune Disorders to 2017 - Pipeline Analysis | 54 | 13 |
| Research and Development Pipeline by Phase | 54 | 1 |
| Research and Development Pipeline by Indication | 55 | 1 |
| Idiopathic Thrombocytopenic Purpura (ITP): Research and Development Pipeline | 56 | 1 |
| Overview | 56 | 1 |
| Pipeline by Clinical Phases of Development | 57 | 1 |
| Preclinical | 57 | 1 |
| Phase I | 57 | 1 |
| Phase II | 57 | 1 |
| Phase III | 57 | 1 |
| Myasthenia Gravis: Research and Development Pipeline | 58 | 1 |
| Overview | 58 | 1 |
| Pipeline by Clinical Phases of Development | 59 | 1 |
| IND Filled | 59 | 1 |
| Phase II | 59 | 1 |
| Phase III/NDA Filed | 59 | 1 |
| Amyotrophic Lateral Sclerosis (ALS): Research and Development Pipeline | 60 | 1 |
| Overview | 60 | 1 |
| Pipeline by Clinical Phases of Development | 61 | 1 |
| Discovery | 61 | 1 |
| Preclinical/IND Filed | 62 | 1 |
| Phase I | 63 | 1 |
| Phase II | 63 | 1 |
| Phase III | 64 | 1 |
| Promising Drugs under Clinical Development for Orphan Autoimmune Disorders | 64 | 1 |
| Venoglobulin-IH | 64 | 1 |
| Overview | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| Clinical Trial Management | 64 | 1 |
| Gammaplex | 65 | 1 |
| Overview | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| Clinical Trial Management | 65 | 1 |
| IGIV3I Grifols | 65 | 1 |
| Overview | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| Clinical Trial Management | 66 | 1 |
| Olesoxime (TRO19622) | 66 | 1 |
| Overview | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| Clinical Trial Management | 66 | 1 |
| Orphan Autoimmune Disorders to 2017 - Competitive Profiling | 67 | 6 |
| Amgen Inc. | 67 | 1 |
| Company Overview | 67 | 1 |
| Marketed Products for Orphan Autoimmune Disorders | 67 | 1 |
| SWOT Analysis | 67 | 1 |
| GlaxoSmithKline | 68 | 1 |
| Company Overview | 68 | 1 |
| Marketed Products for Orphan Autoimmune Disorders | 68 | 1 |
| SWOT Analysis | 68 | 1 |
| CSL Behring LLC | 69 | 1 |
| Company Overview | 69 | 1 |
| Marketed Products for Orphan Autoimmune Disorders | 69 | 1 |
| SWOT Analysis | 69 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 70 | 1 |
| Company Overview | 70 | 1 |
| Orphan Autoimmune Disorders- R&D Pipeline | 70 | 1 |
| SWOT Analysis | 70 | 1 |
| Biogen Idec. | 71 | 1 |
| Company Overview | 71 | 1 |
| Orphan Autoimmune Disorders- R&D Pipeline | 71 | 1 |
| SWOT Analysis | 72 | 1 |
| Orphan Autoimmune Disorders to 2017 - Strategic Consolidations | 73 | 8 |
| Overview | 73 | 1 |
| Segmentation by Year | 74 | 1 |
| Segmentation by Indication | 75 | 1 |
| Segmentation by Geography | 76 | 1 |
| Segmentation by Deal Value | 77 | 1 |
| Major Mergers and Acquisitions (M&A) | 78 | 1 |
| Major Licensing Agreements | 79 | 1 |
| Major Co-Development Deals | 80 | 1 |
| Orphan Autoimmune Disorders to 2017 - Appendix | 81 | 8 |
| Market Definitions | 81 | 1 |
| Abbreviations | 81 | 1 |
| Research Methodology | 82 | 6 |
| Coverage | 82 | 1 |
| Secondary Research | 83 | 1 |
| Primary Research | 83 | 1 |
| Therapeutic Landscape | 84 | 1 |
| Epidemiology-based Forecasting | 84 | 2 |
| Market Size by Geography | 86 | 1 |
| Geographical Landscape | 87 | 1 |
| Pipeline Analysis | 87 | 1 |
| Competitive Landscape | 87 | 1 |
| Expert Panel Validation | 87 | 1 |
| Contact Us | 87 | 1 |
| Disclaimer | 87 | 1 |
| Sources | 88 | 1 |